{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:19:36Z","timestamp":1790039976712,"version":"4.0.1"},"reference-count":157,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Remarkable progress has been made in the past decade in the treatment and in the understanding of the biology of childhood lymphoid and myeloid leukemias. With contemporary improved risk assessment, chemotherapy, hematopoietic stem cell transplantation and supportive care, approximately 80% of children with newly diagnosed acute lymphoblastic leukemia and 50% of those with myeloid neoplasm can be cured to date. Current emphasis is placed not only on increased cure rate but also on improved quality of life.<\/jats:p><jats:p>In Section I, Dr. Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of contemporary treatment programs. He emphasizes that treatment failure in some patients is not due to intrinsic drug resistance of leukemic cells but is rather caused by suboptimal drug dosing due to host compliance, pharmacodynamics, and pharmacogenetics. Hence, measurement of minimal residual disease, which accounts for both the genetic (primary and secondary) features of leukemic lymphoblasts and pharmacogenomic variables of the host, is the most reliable prognostic indicator. Finally, he contends that with optimal risk-directed systemic and intrathecal therapy, cranial irradiation may be omitted in all patients, regardless of the presenting features.<\/jats:p><jats:p>In Section II, Dr. Martin Schrappe performs detailed analyses of the prognostic impact of presenting age, leukocyte count, sex, immunophenotype, genetic abnormality, early treatment response, and in vitro drug sensitivity\/resistance in childhood acute lymphoblastic leukemia, based on the large database of the Berlin-Frankfurt-Mu\u0308nster consortium. He also succinctly summarizes the important treatment components resulting in the improved outcome of children and young adolescents with this disease. He describes the treatment approach that led to the improved outcome of adolescent patients, a finding that may be applied to young adults in the second and third decade of life. Finally, he believes that treatment reduction under well-controlled clinical trials is feasible in a subgroup of patients with excellent early treatment response as evidenced by minimal residual disease measurement during induction and consolidation therapy.<\/jats:p><jats:p>In Section III, Dr. Raul Ribeiro describes distinct morphologic and genetic subtypes of acute myeloid leukemia. The finding of essentially identical gene expression profiling by DNA microarray in certain specific genetic subtypes of childhood and adult acute myeloid leukemia suggests a shared leukemogenesis. He then describes the principles of treatment as well as the efficacy and toxicity of various forms of postremission therapy, emphasizing the need of tailoring therapy to both the disease and the age of the patient. Early results suggest that minimal residual disease measurement can also improve the risk assessment in acute myeloid leukemia, and that cranial irradiation can be omitted even in those with central-nervous-system leukemia at diagnosis.<\/jats:p><jats:p>In Section IV, Dr. Charlotte Niemeyer describes a new classification of myelodysplastic and myeloproliferative diseases in childhood, which has greatly facilitated the diagnosis of myelodysplastic syndromes and juvenile myelomonocytic leukemia. The recent discovery of somatic mutations in PTPN11 has improved the understanding of the pathobiology and the diagnosis of juvenile myelomonocytic leukemia. Together with the findings of mutations in RAS and NF1 in the other patients, she suggests that pathological activation of RAS-dependent pathways plays a central role in the leukemogenesis of this disease. She then describes the various treatment approaches for both juvenile myelomonocytic leukemia and myelodysplastic syndromes in the US and Europe, emphasizing the differences between childhood and adult cases for the latter group of diseases. She also raises some controversial issues regarding treatment that will require well-controlled international clinical trials to address.<\/jats:p>","DOI":"10.1182\/asheducation-2004.1.118","type":"journal-article","created":{"date-parts":[[2004,11,20]],"date-time":"2004-11-20T02:03:01Z","timestamp":1100916181000},"page":"118-145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":89,"title":["Childhood and Adolescent Lymphoid and Myeloid Leukemia"],"prefix":"10.1182","volume":"2004","author":[{"given":"Ching-Hon","family":"Pui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul C.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte M.","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021215282895100_R1","doi-asserted-by":"crossref","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211\u20131218.","DOI":"10.1182\/blood.V97.5.1211"},{"key":"2020021215282895100_R2","doi-asserted-by":"crossref","unstructured":"Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003;290:2001\u20132007.","DOI":"10.1001\/jama.290.15.2001"},{"key":"2020021215282895100_R3","doi-asserted-by":"crossref","unstructured":"Pui CH, Schrappe M, Masera G, et al. Ponte di Legno Working Group: statement on the right of children to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia. 2004;18:1043\u20131053.","DOI":"10.1038\/sj.leu.2403365"},{"key":"2020021215282895100_R4","doi-asserted-by":"crossref","unstructured":"Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia\u2014current status and future perspectives. Lancet Oncol. 2001;2:597\u2013607.","DOI":"10.1016\/S1470-2045(01)00516-2"},{"key":"2020021215282895100_R5","doi-asserted-by":"crossref","unstructured":"Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663\u20131671.","DOI":"10.1056\/NEJM199806043382304"},{"key":"2020021215282895100_R6","unstructured":"Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310\u20133322."},{"key":"2020021215282895100_R7","doi-asserted-by":"crossref","unstructured":"Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535\u20131548.","DOI":"10.1056\/NEJMra023001"},{"key":"2020021215282895100_R8","doi-asserted-by":"crossref","unstructured":"Arico\u0300 M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998\u20131006.","DOI":"10.1056\/NEJM200004063421402"},{"key":"2020021215282895100_R9","doi-asserted-by":"crossref","unstructured":"Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet2002;359:1909\u20131915.","DOI":"10.1016\/S0140-6736(02)08782-2"},{"key":"2020021215282895100_R10","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Look AT. Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003;40:274\u2013280.","DOI":"10.1016\/S0037-1963(03)00195-1"},{"key":"2020021215282895100_R11","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103:3544\u20133546.","DOI":"10.1182\/blood-2003-07-2441"},{"key":"2020021215282895100_R12","doi-asserted-by":"crossref","unstructured":"Holleman A, Cheok MH, den Boer ML, et al. Gene expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533\u2013542.","DOI":"10.1056\/NEJMoa033513"},{"key":"2020021215282895100_R13","doi-asserted-by":"crossref","unstructured":"Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2002;15:741\u2013756.","DOI":"10.1053\/beha.2002.0225"},{"key":"2020021215282895100_R14","doi-asserted-by":"crossref","unstructured":"Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464\u2013468.","DOI":"10.1038\/nature02626"},{"key":"2020021215282895100_R15","doi-asserted-by":"crossref","unstructured":"Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet. 2002;359:1033\u20131034.","DOI":"10.1016\/S0140-6736(02)08065-0"},{"key":"2020021215282895100_R16","doi-asserted-by":"crossref","unstructured":"Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children\u2019s Research Hospital. Blood. July 13, 2004;DOI 10.1182\/blood-2004-04-1616.","DOI":"10.1182\/blood-2004-04-1616"},{"key":"2020021215282895100_R17","unstructured":"Pui CH, Relling MV, Sandlund JT, et al. Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol. 2004;83 (Suppl 1):S124\u2013126."},{"key":"2020021215282895100_R18","unstructured":"Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640\u2013649. Erratum in: N Engl J Med 2003;349:1299."},{"key":"2020021215282895100_R19","doi-asserted-by":"crossref","unstructured":"Pui CH. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 2003;21:179\u2013181.","DOI":"10.1200\/JCO.2003.10.032"},{"key":"2020021215282895100_R20","doi-asserted-by":"crossref","unstructured":"Howard SC, Gajjar AJ, Cheng C, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA. 2002;288:2001\u20132007.","DOI":"10.1001\/jama.288.16.2001"},{"key":"2020021215282895100_R21","doi-asserted-by":"crossref","unstructured":"Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982\u20131995. Leukemia. 2000;14:2196\u20132204.","DOI":"10.1038\/sj.leu.2401963"},{"key":"2020021215282895100_R22","doi-asserted-by":"crossref","unstructured":"Gaynon PS, Trigg ME, Heerema NA, et al. Children\u2019s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983\u20131995. Leukemia. 2000;14:2223\u20132233.","DOI":"10.1038\/sj.leu.2401939"},{"key":"2020021215282895100_R23","doi-asserted-by":"crossref","unstructured":"Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 2000;14:2205\u20132222.","DOI":"10.1038\/sj.leu.2401973"},{"key":"2020021215282895100_R24","doi-asserted-by":"crossref","unstructured":"Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14:2257\u20132266.","DOI":"10.1038\/sj.leu.2401960"},{"key":"2020021215282895100_R25","doi-asserted-by":"crossref","unstructured":"Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia. 2000;14:2267\u20132275.","DOI":"10.1038\/sj.leu.2401961"},{"key":"2020021215282895100_R26","doi-asserted-by":"crossref","unstructured":"Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605\u2013615.","DOI":"10.1056\/NEJM199808273390907"},{"key":"2020021215282895100_R27","unstructured":"Schrappe M, Arico M, Harbott J, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730\u20132741."},{"key":"2020021215282895100_R28","doi-asserted-by":"crossref","unstructured":"Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463\u2013473.","DOI":"10.1038\/sj.leu.2400959"},{"key":"2020021215282895100_R29","doi-asserted-by":"crossref","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA- 94 trials. J Clin Oncol. 2003;21:774\u2013780.","DOI":"10.1200\/JCO.2003.02.053"},{"key":"2020021215282895100_R30","doi-asserted-by":"crossref","unstructured":"Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696\u20131707.","DOI":"10.1038\/sj.leu.2401555"},{"key":"2020021215282895100_R31","doi-asserted-by":"crossref","unstructured":"Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122\u20133133.","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"2020021215282895100_R32","unstructured":"Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310\u20133322."},{"key":"2020021215282895100_R33","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Thiel E, Lo\u0308ffler H, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood. 1984;64:38\u201347.","DOI":"10.1182\/blood.V64.1.38.38"},{"key":"2020021215282895100_R34","unstructured":"Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL\/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094\u20131099."},{"key":"2020021215282895100_R35","doi-asserted-by":"crossref","unstructured":"Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209\u20131217.","DOI":"10.1182\/blood.V94.4.1209"},{"key":"2020021215282895100_R36","doi-asserted-by":"crossref","unstructured":"Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003;17:700\u2013706.","DOI":"10.1038\/sj.leu.2402883"},{"key":"2020021215282895100_R37","doi-asserted-by":"crossref","unstructured":"Nachman J, Sather HN, Buckley JD, et al. Young adults 16\u201321 years of age at diagnosis entered on Children\u2019s Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993;71:3377\u20133385","DOI":"10.1002\/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8"},{"key":"2020021215282895100_R38","doi-asserted-by":"crossref","unstructured":"Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood. 1986;67:415\u2013420","DOI":"10.1182\/blood.V67.2.415.415"},{"key":"2020021215282895100_R39","doi-asserted-by":"crossref","unstructured":"Reichel M, Gillert E, Angermuller S, et al. Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL. Oncogene. 2001;20:2900\u20132907.","DOI":"10.1038\/sj.onc.1204401"},{"key":"2020021215282895100_R40","doi-asserted-by":"crossref","unstructured":"Scholz I, Popp S, Granzow M, et al. Comparative genomic hybridization in childhood acute lymphoblastic leukemia. correlation with interphase cytogenetics and loss of heterozygosity analysis. Cancer Genet Cytogenet. 2001;124:89\u201397.","DOI":"10.1016\/S0165-4608(00)00330-7"},{"key":"2020021215282895100_R41","doi-asserted-by":"crossref","unstructured":"van der Burg M, Poulsen TS, Hunger SP, et al. Split-signal FISH for detection of chromosome aberrations in acute lymphoblastic leukemia. Leukemia. 2004;18:895\u2013908.","DOI":"10.1038\/sj.leu.2403340"},{"key":"2020021215282895100_R42","doi-asserted-by":"crossref","unstructured":"Cave H, Suciu S, Preudhomme C, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951. Blood. 2004;103:442\u2013450. Epub 2003 Sep 2022.","DOI":"10.1182\/blood-2003-05-1495"},{"key":"2020021215282895100_R43","doi-asserted-by":"crossref","unstructured":"Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531\u2013537.","DOI":"10.1126\/science.286.5439.531"},{"key":"2020021215282895100_R44","doi-asserted-by":"crossref","unstructured":"Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, Relling MV, Evans WE. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet. 2003;34:85\u201390.","DOI":"10.1038\/ng1151"},{"key":"2020021215282895100_R45","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41\u201347.","DOI":"10.1038\/ng765"},{"key":"2020021215282895100_R46","doi-asserted-by":"crossref","unstructured":"Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004;103:1043\u20131049. Epub 2003 Oct 1042.","DOI":"10.1182\/blood-2003-05-1518"},{"key":"2020021215282895100_R47","doi-asserted-by":"crossref","unstructured":"Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004;103:2771\u20132778. Epub 2003 Dec 2718.","DOI":"10.1182\/blood-2003-09-3243"},{"key":"2020021215282895100_R48","doi-asserted-by":"crossref","unstructured":"Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004;125:552\u2013559.","DOI":"10.1111\/j.1365-2141.2004.04948.x"},{"key":"2020021215282895100_R49","doi-asserted-by":"crossref","unstructured":"Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL\/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571\u2013577.","DOI":"10.1182\/blood.V90.2.571"},{"key":"2020021215282895100_R50","doi-asserted-by":"crossref","unstructured":"Aguiar RC, Sohal J, van Rhee F, et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br. J. Haematol. 1996;95:673\u2013677.","DOI":"10.1046\/j.1365-2141.1996.d01-1946.x"},{"key":"2020021215282895100_R51","doi-asserted-by":"crossref","unstructured":"Whitehead VM, Payment C, Cooley L, et al. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia. 2001;15:1081\u20131088.","DOI":"10.1038\/sj.leu.2402165"},{"key":"2020021215282895100_R52","doi-asserted-by":"crossref","unstructured":"Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome- positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998\u20131006.","DOI":"10.1056\/NEJM200004063421402"},{"key":"2020021215282895100_R53","doi-asserted-by":"crossref","unstructured":"Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909\u20131915.","DOI":"10.1016\/S0140-6736(02)08782-2"},{"key":"2020021215282895100_R54","doi-asserted-by":"crossref","unstructured":"Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717\u20131726.","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B"},{"key":"2020021215282895100_R55","doi-asserted-by":"crossref","unstructured":"Gajjar A, Ribeiro R, Hancock ML, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood. 1995;86:1292\u20131295.","DOI":"10.1182\/blood.V86.4.1292.bloodjournal8641292"},{"key":"2020021215282895100_R56","doi-asserted-by":"crossref","unstructured":"Arico M, Basso G, Mandelli F, et al. Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer. 1995;75:1684\u20131693.","DOI":"10.1002\/1097-0142(19950401)75:7<1684::AID-CNCR2820750720>3.0.CO;2-2"},{"key":"2020021215282895100_R57","unstructured":"Ludwig WD, Rieder H, Bartram CR, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03\/87 and 04\/89. Blood. 1998;92:1898\u20131909."},{"key":"2020021215282895100_R58","unstructured":"Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92:1556\u20131564."},{"key":"2020021215282895100_R59","doi-asserted-by":"crossref","unstructured":"Lauten M, Stanulla M, Zimmermann M, Welte K, Riehm H, Schrappe M. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter. Klin Padiatr. 2001;213:169\u2013174.","DOI":"10.1055\/s-2001-16848"},{"key":"2020021215282895100_R60","unstructured":"Lauten M, Zimmermann M, Reiter A, et al. Bone marrow day 15 has an additional impact on the prediction of event free survival in children with acute lymphoblastic leukemia characterized by the prednisone response [abstract]. Blood. 2002;100:69a."},{"key":"2020021215282895100_R61","doi-asserted-by":"crossref","unstructured":"Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225\u2013229.","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"2020021215282895100_R62","doi-asserted-by":"crossref","unstructured":"Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001\u20132008.","DOI":"10.1093\/jnci\/91.23.2001"},{"key":"2020021215282895100_R63","doi-asserted-by":"crossref","unstructured":"Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2000;10:715\u2013726.","DOI":"10.1097\/00008571-200011000-00006"},{"key":"2020021215282895100_R64","doi-asserted-by":"crossref","unstructured":"Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:3262\u20133268.","DOI":"10.1200\/JCO.2003.11.031"},{"key":"2020021215282895100_R65","doi-asserted-by":"crossref","unstructured":"Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia\u2014implications for treatment of infants. Leukemia. 1998;12:1344\u20131348.","DOI":"10.1038\/sj.leu.2401129"},{"key":"2020021215282895100_R66","doi-asserted-by":"crossref","unstructured":"Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood. 1998;92:259\u2013266.","DOI":"10.1182\/blood.V92.1.259.413k21_259_266"},{"key":"2020021215282895100_R67","doi-asserted-by":"crossref","unstructured":"Schmiegelow K, Nyvold C, Seyfarth J, et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia. 2001;15:1066\u20131071.","DOI":"10.1038\/sj.leu.2402144"},{"key":"2020021215282895100_R68","doi-asserted-by":"crossref","unstructured":"Frost BM, Forestier E, Gustafsson G, et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia: On behalf of the Nordic Society for Paediatric Haematology and Oncology. Blood. 2004;24:24.","DOI":"10.1182\/blood-2003-12-4426"},{"key":"2020021215282895100_R69","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17:2318\u20132357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"2020021215282895100_R70","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257\u20132317.","DOI":"10.1038\/sj.leu.2403202"},{"key":"2020021215282895100_R71","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood. 2002;100:52\u201358.","DOI":"10.1182\/blood-2002-01-0006"},{"key":"2020021215282895100_R72","doi-asserted-by":"crossref","unstructured":"Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99:1952\u20131958.","DOI":"10.1182\/blood.V99.6.1952"},{"key":"2020021215282895100_R73","doi-asserted-by":"crossref","unstructured":"Neale GA, Coustan-Smith E, Stow P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2004;18:934\u2013938.","DOI":"10.1038\/sj.leu.2403348"},{"key":"2020021215282895100_R74","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Gokbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program).2002:162\u2013192.","DOI":"10.1182\/asheducation-2002.1.162"},{"key":"2020021215282895100_R75","doi-asserted-by":"crossref","unstructured":"Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99:1253\u20131258.","DOI":"10.1182\/blood.V99.4.1253"},{"key":"2020021215282895100_R76","doi-asserted-by":"crossref","unstructured":"Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood. 2002;99:4386\u20134393.","DOI":"10.1182\/blood.V99.12.4386"},{"key":"2020021215282895100_R77","doi-asserted-by":"crossref","unstructured":"van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901\u20131928.","DOI":"10.1038\/sj.leu.2401592"},{"key":"2020021215282895100_R78","doi-asserted-by":"crossref","unstructured":"Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663\u20131671.","DOI":"10.1056\/NEJM199806043382304"},{"key":"2020021215282895100_R79","unstructured":"Goker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia. 1993;7:1000\u20131004."},{"key":"2020021215282895100_R80","doi-asserted-by":"crossref","unstructured":"Frost BM, Lonnerholm G, Koopmans P, et al. Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr. 2003;92:551\u2013557.","DOI":"10.1111\/j.1651-2227.2003.tb02505.x"},{"key":"2020021215282895100_R81","doi-asserted-by":"crossref","unstructured":"Henze G, Langermann H-J, Bra\u0308mswig J, et al. Ergebnisse der Studie BFM 76\/79 zur Behandlung der akuten lymphoblastischen Leuka\u0308mie bei Kindern und Jugendlichen. Klin Pa\u0308diatr. 1981;193:145\u2013154.","DOI":"10.1055\/s-2008-1034450"},{"key":"2020021215282895100_R82","doi-asserted-by":"crossref","unstructured":"Arico M, Valsecchi MG, Conter V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin- Frankfurt-Muenster protocol II. Blood. 2002;100:420\u2013426.","DOI":"10.1182\/blood.V100.2.420"},{"key":"2020021215282895100_R83","doi-asserted-by":"crossref","unstructured":"Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000;88:1964\u20131969.","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1964::AID-CNCR27>3.0.CO;2-1"},{"key":"2020021215282895100_R84","unstructured":"Veerman AJ, Hahlen K, Kamps WA, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J. Clin. Oncol. 1996;14:911\u2013918."},{"key":"2020021215282895100_R85","doi-asserted-by":"crossref","unstructured":"Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19:1040\u20131046.","DOI":"10.1200\/JCO.2001.19.4.1040"},{"key":"2020021215282895100_R86","doi-asserted-by":"crossref","unstructured":"Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Blood. 2003;101:3809\u20133817. Epub 2003 Jan 3816.","DOI":"10.1182\/blood-2002-08-2454"},{"key":"2020021215282895100_R87","doi-asserted-by":"crossref","unstructured":"Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children\u2019s Cancer Group. J Clin Oncol. 1998;16:920\u2013930.","DOI":"10.1200\/JCO.1998.16.3.920"},{"key":"2020021215282895100_R88","doi-asserted-by":"crossref","unstructured":"Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children\u2019s Research Hospital. Leukemia. 2000;14:2286\u20132294.","DOI":"10.1038\/sj.leu.2401938"},{"key":"2020021215282895100_R89","doi-asserted-by":"crossref","unstructured":"Kamps WA, Veerman AJ, van Wering ER, et al. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984\u20131991. Leukemia. 2000;14:2240\u20132246.","DOI":"10.1038\/sj.leu.2401964"},{"key":"2020021215282895100_R90","doi-asserted-by":"crossref","unstructured":"Conter V, Schrappe M, Arico M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol. 1997;15:2786\u20132791.","DOI":"10.1200\/JCO.1997.15.8.2786"},{"key":"2020021215282895100_R91","doi-asserted-by":"crossref","unstructured":"Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798\u20131809.","DOI":"10.1200\/JCO.2003.08.047"},{"key":"2020021215282895100_R92","doi-asserted-by":"crossref","unstructured":"Laver JH, Barredo JC, Amylon M, et al. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. Leukemia. 2000;14:369\u2013373.","DOI":"10.1038\/sj.leu.2401693"},{"key":"2020021215282895100_R93","doi-asserted-by":"crossref","unstructured":"Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2001;96:3381\u20133384.","DOI":"10.1182\/blood.V96.10.3381"},{"key":"2020021215282895100_R94","doi-asserted-by":"crossref","unstructured":"Bu\u0308rger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184\u2013188.","DOI":"10.1200\/JCO.2003.04.096"},{"key":"2020021215282895100_R95","doi-asserted-by":"crossref","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211\u20131218.","DOI":"10.1182\/blood.V97.5.1211"},{"key":"2020021215282895100_R96","doi-asserted-by":"crossref","unstructured":"Uderzo C, Balduzzi A, De LP, et al. Prospective Study on Allogeneic Bone Marrow Transplantation (Allo BMT) versus Chemotherapy (Chemo) for Very High-Risk (VHR) Childhood Acute Lymphoblastic Leukaemia in First Complete Remission. Bone Marrow Transplant. 2001;28:S22\u2013S24.","DOI":"10.1038\/sj.bmt.1703173"},{"key":"2020021215282895100_R97","doi-asserted-by":"crossref","unstructured":"Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002;16:2228\u20132237.","DOI":"10.1038\/sj.leu.2402690"},{"key":"2020021215282895100_R98","doi-asserted-by":"crossref","unstructured":"Childhood-ALL-Collaborative-Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet. 1996;347:1783\u20131788.","DOI":"10.1016\/S0140-6736(96)91615-3"},{"key":"2020021215282895100_R99","doi-asserted-by":"crossref","unstructured":"Mattano LA, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children\u2019s Cancer Group. J Clin Oncol. 2000;18:3262\u20133272.","DOI":"10.1200\/JCO.2000.18.18.3262"},{"key":"2020021215282895100_R100","doi-asserted-by":"crossref","unstructured":"Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122\u20133133.","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"2020021215282895100_R101","unstructured":"Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2014Childhood Leukemia Cooperative Group [see comments]. N Engl J Med. 1998;339:591\u2013598."},{"key":"2020021215282895100_R102","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96:2691\u20132696.","DOI":"10.1182\/blood.V96.8.2691"},{"key":"2020021215282895100_R103","doi-asserted-by":"crossref","unstructured":"van Dongen JJM, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM Study Group. Lancet. 1998;352:1731\u20131738.","DOI":"10.1016\/S0140-6736(98)04058-6"},{"key":"2020021215282895100_R104","doi-asserted-by":"crossref","unstructured":"Harms D, Janka-Schaub G. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89, and 92. Leukemia. 2000;14:2234\u20132239.","DOI":"10.1038\/sj.leu.2401974"},{"key":"2020021215282895100_R105","doi-asserted-by":"crossref","unstructured":"Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981\u20131995). Leukemia. 2000;14:2247\u20132256.","DOI":"10.1038\/sj.leu.2401980"},{"key":"2020021215282895100_R106","doi-asserted-by":"crossref","unstructured":"Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children\u2019s Cancer Study Group 1981\u20131995. Leukemia. 2000;14:2295\u20132306.","DOI":"10.1038\/sj.leu.2401937"},{"key":"2020021215282895100_R107","doi-asserted-by":"crossref","unstructured":"Eden OB, Harrison G, Richards S, et al. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980\u20131997. Medical Research Council Childhood Leukaemia Working Party. Leukemia. 2000;14:2307\u20132320.","DOI":"10.1038\/sj.leu.2401962"},{"key":"2020021215282895100_R108","doi-asserted-by":"crossref","unstructured":"Tenen DG. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003;3:89\u2013101.","DOI":"10.1038\/nrc989"},{"key":"2020021215282895100_R109","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2004."},{"key":"2020021215282895100_R110","unstructured":"Ross ME, Onciu RMM, Liu HC, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004 June 29. Epub ahead of print; DOI 10.1182\/blood-2004-03-1154."},{"key":"2020021215282895100_R111","doi-asserted-by":"crossref","unstructured":"Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell. 2002;2:437\u2013445.","DOI":"10.1016\/S1535-6108(02)00211-8"},{"key":"2020021215282895100_R112","doi-asserted-by":"crossref","unstructured":"Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med. 2004;351:120\u2013121.","DOI":"10.1056\/NEJMp048113"},{"key":"2020021215282895100_R113","doi-asserted-by":"crossref","unstructured":"Lipshultz SE, Rifai N, Dalton VM et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145\u2013153.","DOI":"10.1056\/NEJMoa035153"},{"key":"2020021215282895100_R114","doi-asserted-by":"crossref","unstructured":"de Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22:1404\u20131412.","DOI":"10.1200\/JCO.2004.09.008"},{"key":"2020021215282895100_R115","doi-asserted-by":"crossref","unstructured":"Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood. 2002;99:3801\u20133805.","DOI":"10.1182\/blood.V99.10.3801"},{"key":"2020021215282895100_R116","unstructured":"Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol. 2004;83 Suppl 1:S108\u2013S112."},{"key":"2020021215282895100_R117","doi-asserted-by":"crossref","unstructured":"Byrd JC, Mrozek K, Dodge RK et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325\u20134336.","DOI":"10.1182\/blood-2002-03-0772"},{"key":"2020021215282895100_R118","unstructured":"Hijiya N, Metzger ML, Pounds S et al. Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer. 2004. 2004;43:1\u20137."},{"key":"2020021215282895100_R119","doi-asserted-by":"crossref","unstructured":"Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)\/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462\u2013469.","DOI":"10.1182\/blood-2002-11-3527"},{"key":"2020021215282895100_R120","doi-asserted-by":"crossref","unstructured":"Razzouk BI, Raimondi SC, Srivastava DK, et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution\u2019s experience. Leukemia. 2001;15:1326\u20131330.","DOI":"10.1038\/sj.leu.2402215"},{"key":"2020021215282895100_R121","doi-asserted-by":"crossref","unstructured":"Byrd JC, Ruppert AS, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087\u20131094.","DOI":"10.1200\/JCO.2004.07.012"},{"key":"2020021215282895100_R122","doi-asserted-by":"crossref","unstructured":"Razzouk BI, Raimondi SC, Srivastava DK et al. Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution\u2019s experience. Leukemia. 2001;15:1326\u20131330.","DOI":"10.1038\/sj.leu.2402215"},{"key":"2020021215282895100_R123","doi-asserted-by":"crossref","unstructured":"Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302\u20132309.","DOI":"10.1200\/JCO.2002.08.023"},{"key":"2020021215282895100_R124","doi-asserted-by":"crossref","unstructured":"Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down\u2019s syndrome: results of NOPHO-AML trials. Br J Haematol. 2003;122:217\u2013225.","DOI":"10.1046\/j.1365-2141.2003.04418.x"},{"key":"2020021215282895100_R125","doi-asserted-by":"crossref","unstructured":"Mundschau G, Gurbuxani S, Gamis AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298\u20134300.","DOI":"10.1182\/blood-2002-12-3904"},{"key":"2020021215282895100_R126","doi-asserted-by":"crossref","unstructured":"Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution\u2019s experience. Blood. 2001;97:3727\u20133732.","DOI":"10.1182\/blood.V97.12.3727"},{"key":"2020021215282895100_R127","doi-asserted-by":"crossref","unstructured":"O\u2019Brien TA, Russell SJ, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children\u2019s Cancer Study Group. Blood. 2002;100:2708\u20132716.","DOI":"10.1182\/blood.V100.8.2708"},{"key":"2020021215282895100_R128","doi-asserted-by":"crossref","unstructured":"Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council\u2019s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311\u20132318.","DOI":"10.1182\/blood.V89.7.2311"},{"key":"2020021215282895100_R129","doi-asserted-by":"crossref","unstructured":"Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705\u20132713.","DOI":"10.1200\/JCO.2001.19.10.2705"},{"key":"2020021215282895100_R130","doi-asserted-by":"crossref","unstructured":"Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89\/91. Leucamie Aique Myeloide Enfant. J Clin Oncol. 2002;20:2774\u201382.","DOI":"10.1200\/JCO.2002.07.300"},{"key":"2020021215282895100_R131","doi-asserted-by":"crossref","unstructured":"Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med. 1996; 334:1428\u20131434.","DOI":"10.1056\/NEJM199605303342203"},{"key":"2020021215282895100_R132","doi-asserted-by":"crossref","unstructured":"Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children\u2019s Cancer Group. Blood. 1996;87:4979\u20134989.","DOI":"10.1182\/blood.V87.12.4979.bloodjournal87124979"},{"key":"2020021215282895100_R133","doi-asserted-by":"crossref","unstructured":"Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001;19:2804\u20132811.","DOI":"10.1200\/JCO.2001.19.11.2804"},{"key":"2020021215282895100_R134","doi-asserted-by":"crossref","unstructured":"Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution\u2019s experience. Leukemia. 2003;17:2090\u20132096.","DOI":"10.1038\/sj.leu.2403131"},{"key":"2020021215282895100_R135","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol. 2003;123:243\u2013252.","DOI":"10.1046\/j.1365-2141.2003.04610.x"},{"key":"2020021215282895100_R136","doi-asserted-by":"crossref","unstructured":"Webb DKH, Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia. 1999;13:25\u201331.","DOI":"10.1038\/sj.leu.2401254"},{"key":"2020021215282895100_R137","doi-asserted-by":"crossref","unstructured":"Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89\/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377\u20134385.","DOI":"10.1200\/JCO.2003.11.066"},{"key":"2020021215282895100_R138","doi-asserted-by":"crossref","unstructured":"Hasle H, Niemeyer CM, Chessells JM et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277\u2013282.","DOI":"10.1038\/sj.leu.2402765"},{"key":"2020021215282895100_R139","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001."},{"key":"2020021215282895100_R140","doi-asserted-by":"crossref","unstructured":"Tartaglia M, Niemeyer CM, Song X et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34(2):148\u2013150.","DOI":"10.1038\/ng1156"},{"key":"2020021215282895100_R141","unstructured":"Niemeyer CM, Arico\u0300 M , Basso G, et al. Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood. 1997;89:3534\u20133543."},{"key":"2020021215282895100_R142","doi-asserted-by":"crossref","unstructured":"CM Niemeyer, S Fenu, H Hasle, et al. Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood. 1998;91:365\u2013367.","DOI":"10.1182\/blood.V91.1.365"},{"key":"2020021215282895100_R143","doi-asserted-by":"crossref","unstructured":"Emanuel PD Myelodysplastic and myeloproliferative disorders in childhood: an update. Br J Haematol. 1999;105:852\u2013863.","DOI":"10.1111\/j.1365-2141.1999.01435.x"},{"key":"2020021215282895100_R144","doi-asserted-by":"crossref","unstructured":"Braun BS, Tuveson DA, Kong N, et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101:597\u2013602.","DOI":"10.1073\/pnas.0307203101"},{"key":"2020021215282895100_R145","doi-asserted-by":"crossref","unstructured":"Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92(1):267\u2013272.","DOI":"10.1182\/blood.V92.1.267.413a31_267_272"},{"key":"2020021215282895100_R146","doi-asserted-by":"crossref","unstructured":"Le DT, Kong N, Zhu Y et al. Somatic inactivation of NF1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 2004;103:4243\u20134250.","DOI":"10.1182\/blood-2003-08-2650"},{"key":"2020021215282895100_R147","doi-asserted-by":"crossref","unstructured":"Loh ML, Vattikuti S, Reynolds MG, et al. Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis. Blood. 2004;103:2325\u20132331.","DOI":"10.1182\/blood-2003-09-3287"},{"key":"2020021215282895100_R148","doi-asserted-by":"crossref","unstructured":"Bader-Meunier B, Tchernia G, Mielot F, et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr. 1997;130:885\u2013859.","DOI":"10.1016\/S0022-3476(97)70273-7"},{"key":"2020021215282895100_R149","doi-asserted-by":"crossref","unstructured":"Passmore JS, Chessells J M Kempski H, et al. Paediatric MDS and JMML in the UK: a population based study of incidence and survival. Br J Haematol. 2003;121; 758\u2013767.","DOI":"10.1046\/j.1365-2141.2003.04361.x"},{"key":"2020021215282895100_R150","doi-asserted-by":"crossref","unstructured":"Locatelli, F., No\u0308llke, P., Zecca, M. et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomoncytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial. Blood. 2004 Sept 7 [Epub ahead of print]","DOI":"10.1182\/blood-2004-05-1944"},{"key":"2020021215282895100_R151","doi-asserted-by":"crossref","unstructured":"Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia. 2002;16:645\u2013649.","DOI":"10.1038\/sj.leu.2402407"},{"key":"2020021215282895100_R152","doi-asserted-by":"crossref","unstructured":"Yoshimi A, Matthes-Martin S, Duffner U et al. Donor leukocyte infusion (DLI) after stem cell transplantation (SCT) in patients with juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant. 2004;33:S172.","DOI":"10.1182\/blood.V104.11.5001.5001"},{"key":"2020021215282895100_R153","unstructured":"Chang Y-H, Jou S-T, Lin D-T et al. Second allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: case report and literature review. J Pediatr Hematol Oncol. 2004;6:190\u2013193."},{"key":"2020021215282895100_R154","doi-asserted-by":"crossref","unstructured":"Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 cases with particular reference to monosomy 7. Blood. 2003;102:1997\u20132003.","DOI":"10.1182\/blood-2002-11-3444"},{"key":"2020021215282895100_R155","doi-asserted-by":"crossref","unstructured":"Webb DKH, Passmore SJ, Hann IM et al. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990\u201399. Br J Haematol. 2002;117:33\u201339.","DOI":"10.1046\/j.1365-2141.2002.03369.x"},{"key":"2020021215282895100_R156","unstructured":"Woods WG, Barnard DR, Alonzo TA, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children\u2019s Cancer Group. J Clin Oncol. 2002; 20:434\u2013440."},{"key":"2020021215282895100_R157","unstructured":"Niemeyer C M, Duffner U, Bender-Go\u0308tze C et al. AML-Type intensive chemotherapy prior to stem cell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS). Blood. 2000;96:521a."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/118\/1634526\/118_145ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2004\/1\/118\/1634526\/118_145ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T10:31:43Z","timestamp":1682850703000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2004\/1\/118\/18697\/Childhood-and-Adolescent-Lymphoid-and-Myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,1]]},"references-count":157,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2004.1.118","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,1]]}}}